Fractyl Health Inc. has announced results from a two-year follow-up of the Germany Real-World Registry study, highlighting the effectiveness of the Revita procedure. The study demonstrated a median weight loss of 9.6% and a reduction of 1.6% in HbA1c levels in participants with obesity and advanced type 2 diabetes (T2D) after a single Revita procedure. No serious adverse events related to the device or procedure were reported. These findings are consistent with previous studies outside the United States, supporting Revita's potential for long-term metabolic control. The company is also preparing for key data readouts from the ongoing REMAIN-1 study, with results anticipated in the third quarter of 2025 for post-GLP-1 weight maintenance and primary endpoint data expected in the second half of 2026. These milestones aim to evaluate Revita's role in maintaining weight loss and supporting metabolic outcomes after GLP-1 therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.